Viatris Falls Below 200-Day Moving Average - Significant Development for VTRS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 12 2025
0mins
Should l Buy VTRS?
Source: NASDAQ.COM
VTRS Stock Performance: VTRS has a 52-week low of $6.85 and a high of $13.55, with the last trade recorded at $9.96.
Source of Information: The data regarding VTRS's stock performance was sourced from Technical Analysis Channel.com.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to fall
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 15.980
Low
10.00
Averages
13.25
High
16.00
Current: 15.980
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump's New Tariff Plan Triggers Market Volatility
- Tariff Policy Shift: Following the Supreme Court ruling, Trump plans to impose a new 10% global tariff, which could lead to the U.S. needing to refund billions in tariffs to importers; the market reacted with initial gains followed by losses, reflecting investor uncertainty about future trade relations.
- Legal Challenge Outlook: The Supreme Court's ruling that Trump wrongfully invoked the International Emergency Economic Powers Act to implement tariffs pushes the refund issue back to lower courts, indicating that firms will face lengthy legal processes to obtain refunds, potentially impacting their cash flow and investment decisions.
- Cautious Market Sentiment: While geopolitical risks have not historically impacted the stock market significantly, investors may reduce exposure as stocks approach all-time highs, especially with the upcoming Nvidia earnings report raising concerns about potential disappointments, leading to heightened market tension.
- Economic Stimulus Expectations: Despite uncertainties, investors remain hopeful that the fiscal stimulus from last year's legislation will begin to take effect in the coming months, potentially alleviating signs of economic weakness and supporting long-term market growth.
See More
Mapi Pharma to Host Virtual KOL Event on MS Treatments
- KOL Event Announcement: Mapi Pharma will host a virtual KOL event on March 3, 2026, featuring presentations from leading medical experts discussing the treatment landscape for Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Forms of Multiple Sclerosis (RMS), aimed at enhancing awareness of the company's Depot technology.
- Clinical Trial Results: The Phase II trial of GA Depot demonstrated a 96.6% rate of no confirmed disability progression over 12 weeks, with EDSS scores improving from 5.1 at baseline to 4.5 after three years, indicating significant efficacy in stabilizing patient function.
- Product Development Progress: GA Depot is currently under final review in Germany and is set to initiate a global Phase III study for PPMS, showcasing Mapi's strategic positioning and market potential in the multiple sclerosis treatment landscape.
- Expert Insights: The event will feature insights from experts like Dr. Aaron Miller from Icahn School of Medicine and Dr. Carlo Tornatore from MedStar Health, who will share their research findings and clinical experiences in multiple sclerosis, further enhancing Mapi's industry influence.
See More
Investors Favor High Dividend Stocks Amid Market Uncertainty
- Investment Strategy in Turbulent Markets: During times of market turbulence and uncertainty, many investors turn to high dividend stocks, which typically have high free cash flows and reward shareholders with substantial dividends, thereby enhancing investor confidence and market stability.
- High-Yield Stocks in Healthcare: Analysts have rated three high-yield stocks in the healthcare sector, including UnitedHealth Group (UNH), Viatris (VTRS), and CVS Health (CVS), which are favored for their stable cash flows and dividend payments, showcasing the sector's investment appeal.
- Accuracy of Analyst Ratings: Among numerous analysts, the most accurate ratings for these high dividend stocks provide crucial investment insights, assisting investors in making more informed decisions in uncertain market conditions.
- Strategic Importance of Dividend Payments: High dividend stocks not only offer investors a stable income source but may also provide some protection during market volatility, reflecting companies' strategic emphasis on financial health and shareholder returns.
See More
SPYD ETF 52-Week Price Analysis
- Price Range Analysis: The SPYD ETF has a 52-week low of $37.92 and a high of $48.38, with the latest trade at $48.26, indicating stability near its high point, which aids investors in assessing market performance.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to identify market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, with investors buying and selling 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), as these liquidity shifts can affect the performance of individual stocks held within the ETFs.
See More
US Stocks Rise on Monday as Tech Stocks Rebound
- Market Recovery: The S&P 500 Index rose by 0.47% on Monday, with the Dow Jones Industrial Average hitting an all-time high, indicating a strong recovery in the market following rebounds in tech stocks and chipmakers, reflecting investor confidence in economic recovery.
- Precious Metals Surge: Mining stocks rallied as gold prices increased by 2% and silver surged over 6%, with Coeur Mining and Hecla Mining gaining more than 7% and 5% respectively, highlighting the positive impact of strong performance in the precious metals market on related stocks.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth projected at 8.4%, which is likely to further boost market sentiment and enhance investor confidence.
- Economic Data Focus: The market will closely watch upcoming economic data releases, including the employment cost index and retail sales figures, which are expected to significantly influence future monetary policy and market trends.
See More
UBS Upgrades Viatris to Buy, Raises Price Target to $11
- Rating Upgrade: UBS upgraded Viatris from Neutral to Buy and raised its price target from $8 to $11 per share, reflecting confidence in the company's growth prospects and likely attracting more investor interest.
- Pipeline Growth: Analyst Ashwani Verma noted that the new product cycle and potential cost savings assumptions for Viatris will further drive performance, which is expected to enhance market demand for its stock.
- Valuation Attractiveness: According to Bloomberg, Viatris trades at 5x consensus EPS estimates for 2027, which Verma identified as
See More
Trump's New Tariff Plan Triggers Market Volatility
- Tariff Policy Shift: Following the Supreme Court ruling, Trump plans to impose a new 10% global tariff, which could lead to the U.S. needing to refund billions in tariffs to importers; the market reacted with initial gains followed by losses, reflecting investor uncertainty about future trade relations.
- Legal Challenge Outlook: The Supreme Court's ruling that Trump wrongfully invoked the International Emergency Economic Powers Act to implement tariffs pushes the refund issue back to lower courts, indicating that firms will face lengthy legal processes to obtain refunds, potentially impacting their cash flow and investment decisions.
- Cautious Market Sentiment: While geopolitical risks have not historically impacted the stock market significantly, investors may reduce exposure as stocks approach all-time highs, especially with the upcoming Nvidia earnings report raising concerns about potential disappointments, leading to heightened market tension.
- Economic Stimulus Expectations: Despite uncertainties, investors remain hopeful that the fiscal stimulus from last year's legislation will begin to take effect in the coming months, potentially alleviating signs of economic weakness and supporting long-term market growth.
See More
Mapi Pharma to Host Virtual KOL Event on MS Treatments
- KOL Event Announcement: Mapi Pharma will host a virtual KOL event on March 3, 2026, featuring presentations from leading medical experts discussing the treatment landscape for Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Forms of Multiple Sclerosis (RMS), aimed at enhancing awareness of the company's Depot technology.
- Clinical Trial Results: The Phase II trial of GA Depot demonstrated a 96.6% rate of no confirmed disability progression over 12 weeks, with EDSS scores improving from 5.1 at baseline to 4.5 after three years, indicating significant efficacy in stabilizing patient function.
- Product Development Progress: GA Depot is currently under final review in Germany and is set to initiate a global Phase III study for PPMS, showcasing Mapi's strategic positioning and market potential in the multiple sclerosis treatment landscape.
- Expert Insights: The event will feature insights from experts like Dr. Aaron Miller from Icahn School of Medicine and Dr. Carlo Tornatore from MedStar Health, who will share their research findings and clinical experiences in multiple sclerosis, further enhancing Mapi's industry influence.
See More
Investors Favor High Dividend Stocks Amid Market Uncertainty
- Investment Strategy in Turbulent Markets: During times of market turbulence and uncertainty, many investors turn to high dividend stocks, which typically have high free cash flows and reward shareholders with substantial dividends, thereby enhancing investor confidence and market stability.
- High-Yield Stocks in Healthcare: Analysts have rated three high-yield stocks in the healthcare sector, including UnitedHealth Group (UNH), Viatris (VTRS), and CVS Health (CVS), which are favored for their stable cash flows and dividend payments, showcasing the sector's investment appeal.
- Accuracy of Analyst Ratings: Among numerous analysts, the most accurate ratings for these high dividend stocks provide crucial investment insights, assisting investors in making more informed decisions in uncertain market conditions.
- Strategic Importance of Dividend Payments: High dividend stocks not only offer investors a stable income source but may also provide some protection during market volatility, reflecting companies' strategic emphasis on financial health and shareholder returns.
See More
SPYD ETF 52-Week Price Analysis
- Price Range Analysis: The SPYD ETF has a 52-week low of $37.92 and a high of $48.38, with the latest trade at $48.26, indicating stability near its high point, which aids investors in assessing market performance.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to identify market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, with investors buying and selling 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), as these liquidity shifts can affect the performance of individual stocks held within the ETFs.
See More
US Stocks Rise on Monday as Tech Stocks Rebound
- Market Recovery: The S&P 500 Index rose by 0.47% on Monday, with the Dow Jones Industrial Average hitting an all-time high, indicating a strong recovery in the market following rebounds in tech stocks and chipmakers, reflecting investor confidence in economic recovery.
- Precious Metals Surge: Mining stocks rallied as gold prices increased by 2% and silver surged over 6%, with Coeur Mining and Hecla Mining gaining more than 7% and 5% respectively, highlighting the positive impact of strong performance in the precious metals market on related stocks.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth projected at 8.4%, which is likely to further boost market sentiment and enhance investor confidence.
- Economic Data Focus: The market will closely watch upcoming economic data releases, including the employment cost index and retail sales figures, which are expected to significantly influence future monetary policy and market trends.
See More
UBS Upgrades Viatris to Buy, Raises Price Target to $11
- Rating Upgrade: UBS upgraded Viatris from Neutral to Buy and raised its price target from $8 to $11 per share, reflecting confidence in the company's growth prospects and likely attracting more investor interest.
- Pipeline Growth: Analyst Ashwani Verma noted that the new product cycle and potential cost savings assumptions for Viatris will further drive performance, which is expected to enhance market demand for its stock.
- Valuation Attractiveness: According to Bloomberg, Viatris trades at 5x consensus EPS estimates for 2027, which Verma identified as
See More
